Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Use of lentiviral pseudotypes as an alternative to reassortant or Triton X-100-treated wild-type Influenza viruses in the neuraminidase inhibition enzyme-linked lectin assay.

Biuso F, Palladino L, Manenti A, Stanzani V, Lapini G, Gao J, Couzens L, Eichelberger MC, Montomoli E.

Influenza Other Respir Viruses. 2019 Sep;13(5):504-516. doi: 10.1111/irv.12669.

2.

Challenges in the development of egg-independent vaccines for influenza.

Trombetta CM, Marchi S, Manini I, Lazzeri G, Montomoli E.

Expert Rev Vaccines. 2019 Jul;18(7):737-750. doi: 10.1080/14760584.2019.1639503. Epub 2019 Jul 22.

PMID:
31265333
3.

Low prevalence of antibodies against pertussis in pregnant women in Italy.

Marchi S, Viviani S, Montomoli E, Trombetta CM.

Lancet Infect Dis. 2019 Jul;19(7):690. doi: 10.1016/S1473-3099(19)30269-5. No abstract available. Erratum in: Lancet Infect Dis. 2019 Aug;19(8):e259.

PMID:
31250813
4.

How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions.

Gianchecchi E, Manenti A, Kistner O, Trombetta C, Manini I, Montomoli E.

Influenza Other Respir Viruses. 2019 Sep;13(5):429-437. doi: 10.1111/irv.12664. Epub 2019 Jun 21.

5.

Measles in pregnancy: a threat for Italian women?

Marchi S, Monti M, Viviani S, Montomoli E, Trombetta CM.

Hum Vaccin Immunother. 2019 Jun 20:1-3. doi: 10.1080/21645515.2019.1621146. [Epub ahead of print]

PMID:
31184988
6.

Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 - 2018 season.

Bella A, Gesualdo F, Orsi A, Arcuri C, Chironna M, Loconsole D, Napoli C, Orsi GB, Manini I, Montomoli E, Alfonsi V, Castrucci MR, Rizzo C.

Expert Rev Vaccines. 2019 Jun;18(6):671-679. doi: 10.1080/14760584.2019.1627206. Epub 2019 Jun 13.

PMID:
31159616
7.

Vaccine Production in Africa: A Feasible Business Model for Capacity Building and Sustainable New Vaccine Introduction.

Makenga G, Bonoli S, Montomoli E, Carrier T, Auerbach J.

Front Public Health. 2019 Mar 20;7:56. doi: 10.3389/fpubh.2019.00056. eCollection 2019.

8.

The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity.

Gianchecchi E, Torelli A, Montomoli E.

Hum Vaccin Immunother. 2019;15(5):1021-1030. doi: 10.1080/21645515.2019.1565269. Epub 2019 Feb 20.

9.

Medicine use and recurrent complaints among 15-years-old adolescents in Tuscany.

Trombetta CM, Manini I, Pammolli A, Rossi S, Pozzi T, Montomoli E, Lazzeri G.

Ann Ist Super Sanita. 2018 Jul-Sep;54(3):208-213. doi: 10.4415/ANN_18_03_07.

10.

Epidemiology and prevention of Human Papillomavirus.

Manini I, Montomoli E.

Ann Ig. 2018 Jul-Aug;30(4 Supple 1):28-32. doi: 10.7416/ai.2018.2231.

11.

Comparison of hemagglutination inhibition, single radial hemolysis, virus neutralization assays, and ELISA to detect antibody levels against seasonal influenza viruses.

Trombetta CM, Remarque EJ, Mortier D, Montomoli E.

Influenza Other Respir Viruses. 2018 Nov;12(6):675-686. doi: 10.1111/irv.12591. Epub 2018 Aug 11.

12.

Impact of erythrocyte species on assays for influenza serology.

Trombetta CM, Ulivieri C, Cox RJ, Remarque EJ, Centi C, Perini D, Piccini G, Rossi S, Marchi S, Montomoli E.

J Prev Med Hyg. 2018 Mar 30;59(1):E1-E7. doi: 10.15167/2421-4248/jpmh2018.59.1.870. eCollection 2018 Mar.

14.

Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults.

Montomoli E, Torelli A, Manini I, Gianchecchi E.

Vaccines (Basel). 2018 Mar 8;6(1). pii: E14. doi: 10.3390/vaccines6010014. Review.

15.

Age and Influenza-Specific Pre-Vaccination Antibodies Strongly Affect Influenza Vaccine Responses in the Icelandic Population whereas Disease and Medication Have Small Effects.

Olafsdottir TA, Alexandersson KF, Sveinbjornsson G, Lapini G, Palladino L, Montomoli E, Del Giudice G, Gudbjartsson DF, Jonsdottir I.

Front Immunol. 2018 Jan 8;8:1872. doi: 10.3389/fimmu.2017.01872. eCollection 2017.

16.

Influenza vaccines: Evaluation of the safety profile.

Trombetta CM, Gianchecchi E, Montomoli E.

Hum Vaccin Immunother. 2018 Mar 4;14(3):657-670. doi: 10.1080/21645515.2017.1423153. Epub 2018 Jan 30. Review.

17.

Egg-Independent Influenza Vaccines and Vaccine Candidates.

Manini I, Trombetta CM, Lazzeri G, Pozzi T, Rossi S, Montomoli E.

Vaccines (Basel). 2017 Jul 18;5(3). pii: E18. doi: 10.3390/vaccines5030018. Review.

18.

An unwanted guest: Neisseria meningitidis - carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence.

Gianchecchi E, Piccini G, Torelli A, Rappuoli R, Montomoli E.

Expert Rev Anti Infect Ther. 2017 Jul;15(7):689-701. doi: 10.1080/14787210.2017.1333422. Epub 2017 May 29. Review.

PMID:
28524748
19.

Water and air ozone treatment as an alternative sanitizing technology.

Martinelli M, Giovannangeli F, Rotunno S, Trombetta CM, Montomoli E.

J Prev Med Hyg. 2017 Mar;58(1):E48-E52.

20.

Epidemiology of herpes simplex virus type 1 and 2 in Italy: a seroprevalence study from 2000 to 2014.

Marchi S, Trombetta CM, Gasparini R, Temperton N, Montomoli E.

J Prev Med Hyg. 2017 Mar;58(1):E27-E33.

21.

Seroprevalence study of Toscana virus and viruses belonging to the Sandfly fever Naples antigenic complex in central and southern Italy.

Marchi S, Trombetta CM, Kistner O, Montomoli E.

J Infect Public Health. 2017 Nov - Dec;10(6):866-869. doi: 10.1016/j.jiph.2017.02.001. Epub 2017 Feb 23.

22.

Retrospective Study Evaluating Seroprevalence of Hepatitis E Virus in Blood Donors and in Swine Veterinarians in Italy (2004).

De Sabato L, Di Bartolo I, Montomoli E, Trombetta C, Ruggeri FM, Ostanello F.

Zoonoses Public Health. 2017 Jun;64(4):308-312. doi: 10.1111/zph.12332. Epub 2016 Dec 2.

PMID:
27911040
23.

Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination.

Manenti A, Tete SM, Mohn KG, Jul-Larsen Å, Gianchecchi E, Montomoli E, Brokstad KA, Cox RJ.

Vaccine. 2017 Jan 3;35(1):191-198. doi: 10.1016/j.vaccine.2016.10.024. Epub 2016 Oct 24.

24.

Early Rise of Blood T Follicular Helper Cell Subsets and Baseline Immunity as Predictors of Persisting Late Functional Antibody Responses to Vaccination in Humans.

Spensieri F, Siena E, Borgogni E, Zedda L, Cantisani R, Chiappini N, Schiavetti F, Rosa D, Castellino F, Montomoli E, Bodinham CL, Lewis DJ, Medini D, Bertholet S, Del Giudice G.

PLoS One. 2016 Jun 23;11(6):e0157066. doi: 10.1371/journal.pone.0157066. eCollection 2016.

25.

Live Attenuated Influenza Vaccine in Children Induces B-Cell Responses in Tonsils.

Mohn KG, Brokstad KA, Pathirana RD, Bredholt G, Jul-Larsen Å, Trieu MC, Lartey SL, Montomoli E, Tøndel C, Aarstad HJ, Cox RJ.

J Infect Dis. 2016 Sep 1;214(5):722-31. doi: 10.1093/infdis/jiw230. Epub 2016 May 30. Erratum in: J Infect Dis. 2016 Oct 3;:.

26.

N. meningitidis and TLR Polymorphisms: A Fascinating Immunomodulatory Network.

Gianchecchi E, Torelli A, Piccini G, Piccirella S, Montomoli E.

Vaccines (Basel). 2016 May 27;4(2). pii: E20. doi: 10.3390/vaccines4020020. Review.

27.

The Safety of Adjuvanted Vaccines Revisited: Vaccine-Induced Narcolepsy.

Ahmed SS, Montomoli E, Pasini FL, Steinman L.

Isr Med Assoc J. 2016 Mar-Apr;18(3-4):216-20. Review.

28.

Fighting Neisseria meningitidis: past and current vaccination strategies.

Piccini G, Torelli A, Gianchecchi E, Piccirella S, Montomoli E.

Expert Rev Vaccines. 2016 Nov;15(11):1393-1407. Epub 2016 May 27. Review.

PMID:
27158988
29.

Influenza immunology evaluation and correlates of protection: a focus on vaccines.

Trombetta CM, Montomoli E.

Expert Rev Vaccines. 2016 Aug;15(8):967-76. doi: 10.1586/14760584.2016.1164046. Epub 2016 Mar 25. Review.

PMID:
26954563
30.

Sea buckthorn bud extract displays activity against cell-cultured Influenza virus.

Torelli A, Gianchecchi E, Piccirella S, Manenti A, Piccini G, Llorente Pastor E, Canovi B, Montomoli E.

J Prev Med Hyg. 2015 Aug 5;56(2):E51-6.

31.

Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children.

Esposito S, Giavoli C, Trombetta C, Bianchini S, Montinaro V, Spada A, Montomoli E, Principi N.

Vaccine. 2016 Jan 2;34(1):56-60. doi: 10.1016/j.vaccine.2015.11.019. Epub 2015 Nov 19.

PMID:
26608327
32.

Emerging Influenza Strains in the Last Two Decades: A Threat of a New Pandemic?

Trombetta C, Piccirella S, Perini D, Kistner O, Montomoli E.

Vaccines (Basel). 2015 Mar 18;3(1):172-85. doi: 10.3390/vaccines3010172. Review.

33.

An Innovative Pseudotypes-Based Enzyme-Linked Lectin Assay for the Measurement of Functional Anti-Neuraminidase Antibodies.

Prevato M, Cozzi R, Pezzicoli A, Taddei AR, Ferlenghi I, Nandi A, Montomoli E, Settembre EC, Bertholet S, Bonci A, Legay F.

PLoS One. 2015 Aug 12;10(8):e0135383. doi: 10.1371/journal.pone.0135383. eCollection 2015.

34.

Neisseria meningitidis infection: who, when and where?

Gianchecchi E, Torelli A, Piccini G, Piccirella S, Montomoli E.

Expert Rev Anti Infect Ther. 2015;13(10):1249-63. doi: 10.1586/14787210.2015.1070096. Epub 2015 Jul 18. Review.

PMID:
26190347
35.

Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2.

Ahmed SS, Volkmuth W, Duca J, Corti L, Pallaoro M, Pezzicoli A, Karle A, Rigat F, Rappuoli R, Narasimhan V, Julkunen I, Vuorela A, Vaarala O, Nohynek H, Pasini FL, Montomoli E, Trombetta C, Adams CM, Rothbard J, Steinman L.

Sci Transl Med. 2015 Jul 1;7(294):294ra105. doi: 10.1126/scitranslmed.aab2354.

PMID:
26136476
36.

Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations.

Eidem S, Tete SM, Jul-Larsen Å, Hoschler K, Montomoli E, Brokstad KA, Cox RJ.

Vaccine. 2015 Aug 7;33(33):4146-54. doi: 10.1016/j.vaccine.2015.05.081. Epub 2015 Jun 7.

PMID:
26057137
37.

Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains.

Lartey S, Pathirana RD, Zhou F, Jul-Larsen Å, Montomoli E, Wood J, Cox RJ.

Hum Vaccin Immunother. 2015;11(7):1654-62. doi: 10.1080/21645515.2015.1048939.

38.

Flucelvax (Optaflu) for seasonal influenza.

Manini I, Domnich A, Amicizia D, Rossi S, Pozzi T, Gasparini R, Panatto D, Montomoli E.

Expert Rev Vaccines. 2015 Jun;14(6):789-804. Review.

PMID:
25968069
39.

Validation of Single Radial Haemolysis assay: A reliable method to measure antibodies against influenza viruses.

Trombetta CM, Perini D, Vitale L, Cox RJ, Stanzani V, Piccirella S, Montomoli E.

J Immunol Methods. 2015 Jul;422:95-101. doi: 10.1016/j.jim.2015.04.009. Epub 2015 Apr 22.

PMID:
25910832
40.

H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix(®) vaccination.

Ambati A, Valentini D, Montomoli E, Lapini G, Biuso F, Wenschuh H, Magalhaes I, Maeurer M.

Immunology. 2015 Jul;145(3):357-66. doi: 10.1111/imm.12448. Epub 2015 Apr 15.

41.

Is influenza A/H10N8 a potential candidate for the next pandemic?

Montomoli E, Trombetta CM.

Pathog Glob Health. 2014 Jul;108(5):213. doi: 10.1179/2047772414Z.000000000215. No abstract available. Erratum in: Pathog Glob Health. 2014 Sep;108(6):302. Maria, Trombetta Claudia [corrected to Trombetta, Claudia Maria].

42.

Discordant correlation between serological assays observed when measuring heterosubtypic responses against avian influenza H5 and H7 viruses in unexposed individuals.

Molesti E, Ferrara F, Lapini G, Montomoli E, Temperton N.

Biomed Res Int. 2014;2014:231365. doi: 10.1155/2014/231365. Epub 2014 Jun 11.

43.

Difference in immune response in vaccinated and unvaccinated Swedish individuals after the 2009 influenza pandemic.

Magalhaes I, Eriksson M, Linde C, Muhammad R, Rane L, Ambati A, Axelsson-Robertson R, Khalaj B, Alvarez-Corrales N, Lapini G, Montomoli E, Linde A, Pedersen NL, Maeurer M.

BMC Infect Dis. 2014 Jun 11;14:319. doi: 10.1186/1471-2334-14-319.

44.

Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge.

Mann AJ, Noulin N, Catchpole A, Stittelaar KJ, de Waal L, Veldhuis Kroeze EJ, Hinchcliffe M, Smith A, Montomoli E, Piccirella S, Osterhaus AD, Knight A, Oxford JS, Lapini G, Cox R, Lambkin-Williams R.

PLoS One. 2014 May 21;9(5):e93761. doi: 10.1371/journal.pone.0093761. eCollection 2014.

45.

Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.

Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E.

Vaccines (Basel). 2014 Oct 13;2(4):707-34. doi: 10.3390/vaccines2040707. Review.

46.

Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines.

Nakowitsch S, Waltenberger AM, Wressnigg N, Ferstl N, Triendl A, Kiefmann B, Montomoli E, Lapini G, Sergeeva M, Muster T, Romanova JR.

Biotechnol J. 2014 Mar;9(3):405-14. doi: 10.1002/biot.201300225. Epub 2013 Dec 10. Erratum in: Biotechnol J. 2014 Apr;9(4):585.

PMID:
24323790
47.

Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison.

Scheifele DW, McNeil SA, Ward BJ, Dionne M, Cooper C, Coleman B, Loeb M, Rubinstein E, McElhaney J, Hatchette T, Li Y, Montomoli E, Schneeberg A, Bettinger JA, Halperin SA; PHAC /CIHR Influenza Research Network.

Hum Vaccin Immunother. 2013 Nov;9(11):2460-73. Epub 2013 Jul 9.

48.

Swine influenza and vaccines: an alternative approach for decision making about pandemic prevention.

Basili M, Ferrini S, Montomoli E.

Eur J Public Health. 2013 Aug;23(4):669-73. doi: 10.1093/eurpub/ckt004. Epub 2013 Mar 26.

PMID:
23531523
49.

A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.

Svindland SC, Pedersen GK, Pathirana RD, Bredholt G, Nøstbakken JK, Jul-Larsen Å, Guzmán CA, Montomoli E, Lapini G, Piccirella S, Jabbal-Gill I, Hinchcliffe M, Cox RJ.

Influenza Other Respir Viruses. 2013 Nov;7(6):1181-93. doi: 10.1111/irv.12056. Epub 2012 Nov 21.

50.

Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.

Montomoli E, Khadang B, Piccirella S, Trombetta C, Mennitto E, Manini I, Stanzani V, Lapini G.

Expert Rev Vaccines. 2012 May;11(5):587-94. doi: 10.1586/erv.12.24. Review.

PMID:
22827244

Supplemental Content

Loading ...
Support Center